Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Oral IIb/IIIa Antiplatelet Development Winding Down; Four Companies Out

Executive Summary

Eight clinical development programs for oral glycoprotein IIb/IIIa receptor antagonists are being closed down in response to lack of compound efficacy.

You may also be interested in...



CombiChem Outside Collaborations May End After Purchase By DuPont

The future of CombiChem's existing collaborations is uncertain following DuPont's announcement that it will acquire the company for approximately $95 mil.

CombiChem Outside Collaborations May End After Purchase By DuPont

The future of CombiChem's existing collaborations is uncertain following DuPont's announcement that it will acquire the company for approximately $95 mil.

Quintiles Increases Contract Win Rate But Suffers From Halt Of Antiplatelets

Quintiles has won about 550 contract bid proposals for drug development work in the U.S. during the first seven months of 1999, according to figures on its success rate provided to analysts during a Sept. 17 conference call.

Related Content

UsernamePublicRestriction

Register

PS034854

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel